Xuelan Zuo
-
- MicroRNA in disease regulation 3
- Hepatology top 10%
-
- Acute Myeloid Leukemia Research 10
- Chronic Myeloid Leukemia Treatments 3
-
- Myeloproliferative Neoplasms: Diagnosis and Treatment 8
- Chronic Lymphocytic Leukemia Research 2
-
- Eosinophilic Disorders and Syndromes 5
-
- Retinoids in leukemia and cellular processes 3
- Kruppel-like factors research 3
- Co-authors
- Xiaorong ZhouYalan YuSanyun WuPing LuoShuo LiXinliang MingJiancheng TuYingying Wang
- Cited by
- Cancer ResearchHepatologyHematology
- Journals
- Journal of Biological Chemistry (1 paper)SHILAP Revista de lepidopterología (1 paper)Blood (3 papers)
- Partner nations
- ChinaUnited States
In The Last Decade
Xuelan Zuo
23 papers receiving 505 citations
Peers
Comparison fields: 5 of 75
- Cancer Research 136
- Hepatology 52
- Hematology 60
- Nutrition and Dietetics 77
- Genetics 49
Countries citing papers authored by Xuelan Zuo
This map shows the geographic impact of Xuelan Zuo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xuelan Zuo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xuelan Zuo more than expected).
Fields of papers citing papers by Xuelan Zuo
This network shows the impact of papers produced by Xuelan Zuo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xuelan Zuo. The network helps show where Xuelan Zuo may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xuelan Zuo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 0 | |
| 7 | 2022 | 32 | |
| 8 | 2021 | 2 | |
| 9 | 2020 | 3 | |
| 10 | 2020 | 5 | |
| 11 | 2019 | 20 | |
| 12 | 2019 | 159 | |
| 13 | 2018 | 8 | |
| 14 | 2016 | 10 | |
| 15 | 2015 | 28 | |
| 16 | 2014 | 50 | |
| 17 | 2014 | 2 | |
| 18 | 2009 | 30 | |
| 19 | [Expression of survivin and P63 protein in B cell non-Hodgkin's lymphoma and their effects on cell apoptosis and proliferation]. | 2007 | 4 |
| 20 | 2006 | 141 |
About Xuelan Zuo
Xuelan Zuo is a scholar working on Hematology, Genetics and Rheumatology, having authored 25 papers that have together received 516 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (10 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Eosinophilic Disorders and Syndromes (5 papers), MicroRNA in disease regulation (3 papers), Chronic Myeloid Leukemia Treatments (3 papers), Retinoids in leukemia and cellular processes (3 papers), Kruppel-like factors research (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). The work is most often cited by research in Cancer Research (136 citations), Hepatology (52 citations) and Hematology (60 citations). Xuelan Zuo has collaborated with scholars based in China and United States. Frequent co-authors include Xiaorong Zhou, Yalan Yu, Sanyun Wu, Ping Luo, Shuo Li, Xinliang Ming, Jiancheng Tu, Yingying Wang, Kejian Zhang and Umid Kumar Shrestha. Their work appears in journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.